BMX
Cytoplasmic tyrosine-protein kinase BMX
As of the edition of 20 October 2026, BMX (cytoplasmic tyrosine-protein kinase BMX, UniProt P51813) has 1 drug tested at it and 1 company on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P51813
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 6
- Disease areas
- Skin and connective tissue; Immune system; Digestive system; Blood and lymph; Bones, joints and muscles; Cancer; Hormones; Infections
- Registered trials of its drugs
- 54
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ritlecitinib | Marketed | Phase 3 | Ends 2041 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Pfizer | Route B |
The other 0 companies at BMX
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at BMX, ranked, with the facts behind eachRequest access. Nothing is shown until you do.